Joslin Diabetes Center, American Well to bring telehealth services to patients nationwide
BOSTON — Joslin Diabetes Center and American Well will collaborate on a telehealth initiative that seeks to improve and expand diabetes patients’ access to high-quality care.
The telehealth services will be powered by American Well’s Online Care technology and will "[apply] a transformative healthcare innovation in support of our mission of improving the lives of people struggling with this disease," Joslin Diabetes Center president and CEO John Brooks said.
"Joslin Diabetes Center is committed to fundamentally changing the landscape of diabetes care today," Brooks said. "Telehealth provides an opportunity to bring together our strengths in research, clinical care, education and awareness in order to create an entirely new class of clinical program — then project care directly to the patients who need it most, at the appropriate time."
"We look forward to joining with Joslin Diabetes Center to help combat a disease that burdens the lives of countless families and, increasingly, our society as a whole," American Well chairman and CEO Ido Schoenberg said. "Joslin is enlisting telehealth in one of its most powerful forms — as a conduit for delivering tailor-made clinical programs to patients who might not otherwise have access to them."
Galen acquires DaunoXome from Gilead
SOUDERTON, Pa. — A Northern Ireland pharmaceutical company has acquired a chemotherapy agent from Gilead.
Galen said it has acquired DaunoXome (daunorubicin citrate liposome injection), an anthracycline chemotherapy agent that was first approved in the United States in 1996, and is indicated as a first-line cytotoxic therapy for advanced HIV-associated Kaposi’s sarcoma. Galen said its wholly owned subsidiary, Galen US, will market the drug in the United States. DaunoXome will be made available through wholesalers in the United States.
“We are delighted that we are now able to supply DaunoXome in the United States for the treatment of patients with this devastating disease,” Galen president Mark Scrutton said, “DaunoXome marks our first step into the oncology arena and this exciting, new acquisition provides us with the opportunity to offer more widely a much-needed therapy for patients with advanced HIV-associated KS.”
Clinic operator Christie Clinic sells two pharmacies to Walgreens
CHAMPAIGN, Ill. — Christie Clinic last week announced it had entered into a purchase agreement with Walgreens for the sale of two of the former’s pharmacy operations.
Walgreens will lease the space currently occupied by Christie Clinic for its new operations. The transfer is expected to be completed by the end of March. Walgreens plans to keep both pharmacy locations open and is renovating the facilities, including new signage.
Both pharmacies will be closed on March 31 and April 1 for minor renovations, as well as operational changes, and will open as Walgreens at 8:00 a.m. on April 2, the clinic operator said.
Christie Clinic operates 14 clinic locations throughout east central Illinois, as well as the Christie Clinic Cancer Center and C U Sleep, which houses the Department of Sleep Medicine.